The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions-Reference-Cited by-同舟云学术

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

Published:2018-04-23 Issue:7 Volume:67 Page:1079-1090
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Zhang Tong,Song Xiaomin,Xu Lanlan,Ma Jie,Zhang Yanjuan,Gong Wenfeng,Zhang Yilu,Zhou Xiaosui,Wang Zuobai,Wang Yali,Shi Yingdi,Bai Huichen,Liu Ning,Yang Xiaolong,Cui Xinxin,Cao Yanping,Liu Qi,Song Jing,Li Yucheng,Tang Zhiyu,Guo Mingming,Wang Lai,Li Kang

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2160-x/fulltext.html

Reference45 articles.

1. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. https://doi.org/10.1126/science.1203486

2. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Investig 117:1137–1146. https://doi.org/10.1172/JCI31405

3. Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig 125:3384–3391. https://doi.org/10.1172/JCI80011

4. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331

5. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study;Oral Oncology;2024-11

2. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China;International Journal of Clinical Pharmacy;2024-09-14

3. Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial;Nature Cancer;2024-09-10

4. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

5. Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study;Clinical and Translational Oncology;2024-08-22